D-dimer increase: an unfavorable factor for patients with primary liver cancer treated with TACE.

abstract：:The metabolic disposition and pharmacokinetics of TNP-470 were investigated in rhesus monkeys following intravenous administration of 5 mg/kg of [3H]-TNP-470. Rapid and extensive metabolism of parent drug to six metabolites occurred as demonstrated by the absence of unchanged drug in plasma and urine at time points as...

journal_title：Cancer chemotherapy and pharmacology

authors： Cretton-Scott E,Placidi L,McClure H,Anderson DC,Sommadossi JP

更新日期：1996-01-01 00:00:00

abstract：PURPOSE:Flavopiridol is primarily a cyclin-dependent kinase-9 inhibitor, and we performed a dose escalation trial to determine the maximum tolerated dose and safety and generate a pharmacokinetic (PK) profile. METHODS:Patients with a diagnosis of relapsed myeloma after at least two prior treatments were included. Flav...

journal_title：Cancer chemotherapy and pharmacology

authors： Hofmeister CC,Poi M,Bowers MA,Zhao W,Phelps MA,Benson DM,Kraut EH,Farag S,Efebera YA,Sexton J,Lin TS,Grever M,Byrd JC

更新日期：2014-02-01 00:00:00

abstract：BACKGROUND AND PURPOSE:The optimal chemotherapeutic protocol for the treatment of esophageal cancer has not yet been established. A dose-escalation study of docetaxel combined with cisplatin and 5-fluorouracil (5-FU) was performed to determine the optimal dose in patients with advanced esophageal squamous cell carcinom...

journal_title：Cancer chemotherapy and pharmacology

authors： Tanaka Y,Yoshida K,Sanada Y,Osada S,Yamaguchi K,Takahashi T

更新日期：2010-11-01 00:00:00

abstract：BACKGROUND:No specific treatment guidelines are available for triple-negative breast cancers, defined by a lack of expression of estrogen (ER), progesterone (PgR), and HER2 receptors. PATIENTS AND METHODS:We investigated in patients with T2-T3 N0-3 ER, PgR <10% and HER2 negative breast cancers the activity both in ter...

journal_title：Cancer chemotherapy and pharmacology

authors： Torrisi R,Balduzzi A,Ghisini R,Rocca A,Bottiglieri L,Giovanardi F,Veronesi P,Luini A,Orlando L,Viale G,Goldhirsch A,Colleoni M

更新日期：2008-09-01 00:00:00

abstract：PURPOSE:Differences in efficacy and toxicity between UDP-glucuronosyltransferase (UGT) 1A1*1/*1 and *1/*6 or *1/*28 genotypes remain unclear in Japanese patients. METHODS:Patients with advanced colorectal cancer who received irinotecan combined with 5-fluorouracil plus l-leucovorin (FOLFIRI) as first-line therapy were...

journal_title：Cancer chemotherapy and pharmacology

authors： Sunakawa Y,Ichikawa W,Fujita K,Nagashima F,Ishida H,Yamashita K,Mizuno K,Miwa K,Kawara K,Akiyama Y,Araki K,Yamamoto W,Miya T,Narabayashi M,Ando Y,Hirose T,Saji S,Sasaki Y

更新日期：2011-08-01 00:00:00

abstract：PURPOSE:The primary objective of this investigation was to compare the extent of brain distribution of the lactone and the carboxylate forms of camptothecin (CPT) and topotecan (TPT) in awake freely moving rats. METHODS:The plasma concentration-time profiles of the lactone and the carboxylate forms of CPT and TPT were...

journal_title：Cancer chemotherapy and pharmacology

authors： El-Gizawy SA,Hedaya MA

更新日期：1999-01-01 00:00:00

abstract：:In rabbits the IV kinetics of MTX (1.33, 4 and 12 mg/kg) could be described by a linear three-compartment model with a terminal half-life between 2.4 and 3.6 h. During 8 h 50% of the dose was excreted into urine in unchanged form and 15% as the metabolite 7-OH-MTX. These fractions remained constant with increasing dos...

journal_title：Cancer chemotherapy and pharmacology

authors： Iven H,Brasch H,Engster J

更新日期：1985-01-01 00:00:00

abstract：BACKGROUND:The presence of hepatic portal venous gas (HPVG) is a rare finding. It is most commonly caused by bowel necrosis and typically carries a grave prognosis. Bevacizumab has emerged as an effective standard therapy in the frontline management of advanced non-small cell lung cancer (NSCLC). Although bevacizumab i...

journal_title：Cancer chemotherapy and pharmacology

authors： Ortega J,Hayes JM,Antonia S

更新日期：2009-12-01 00:00:00

abstract：PURPOSE:The objective of this study was to compare the pharmacokinetics and safety of two tablet formulations containing 500 mg of capecitabine (CAS number 154361-50-9) in patients with colon, colorectal or breast cancer. METHODS:The study was a multicentric, open label, randomized, two-treatment, two-period, two-sequ...

journal_title：Cancer chemotherapy and pharmacology

authors： Chachad S,Purandare S,Malhotra G,Naidu R

更新日期：2013-02-01 00:00:00

abstract：:A phase II trial of idarubicin was performed in 24 patients with advanced lymphoma. The drug was administered in a dose of 10-15 mg/m2 i.v. or 15-70 mg/m2 p.o. (single dose) every 3 weeks. There were four partial responses and four minor responses. All but one of the responders had received prior doxorubicin therapy. ...

journal_title：Cancer chemotherapy and pharmacology

authors： Gillies H,Liang R,Rogers H,Harper P,Parapia L,Cox G,Johnson S

更新日期：1988-01-01 00:00:00

abstract：PURPOSE:The study mainly aimed to determine the biological function of a novelly synthesized phenanthroimidazole derivative, named L233, and to explore its potential mechanisms. METHODS:Cell survival was examined using the MTT assays, and the DNA-damaging role of L233 was explored using the comet assay. Moreover, the ...

journal_title：Cancer chemotherapy and pharmacology

authors： Zhen N,Yang Q,Wu Q,Zhu X,Wang Y,Sun F,Mei W,Yu Y

更新日期：2016-01-01 00:00:00

abstract：PURPOSE:Busulfan (Bu) exposure is critical for efficacy and safety. Body weight (BW), or adjusted ideal body weight (AIBW)-based dosing (WBD) algorithm, has been used in hematopoietic stem cell transplantation (HSCT). A recently completed phase 2 study revealed that 33.6 % of the subjects were under-, or over-exposed, ...

journal_title：Cancer chemotherapy and pharmacology

authors： Wang Y,Kato K,Le Gallo C,Armstrong E,Rock E,Wang X

更新日期：2015-03-01 00:00:00

abstract：PURPOSE:Valproic acid (VPA), a widely used antiepileptic, also inhibits histone deacetylase (HDAC), and is undergoing evaluation as an anti-cancer agent. We studied the pharmacokinetics of VPA in the plasma and cerebrospinal fluid (CSF) in a non-human primate model that is highly predictive of human CSF penetration to ...

journal_title：Cancer chemotherapy and pharmacology

authors： Stapleton SL,Thompson PA,Ou CN,Berg SL,McGuffey L,Gibson B,Blaney SM

更新日期：2008-04-01 00:00:00

abstract：PURPOSE:The purpose of this study was to evaluate the safety and efficacy of low-dose-intensity bevacizumab and weekly irinotecan as salvage treatment for patients with platinum- and taxanes-resistant advanced epithelial ovarian cancer. METHODS:Fifty-two patients with platinum- and taxanes-resistant advanced epithelia...

journal_title：Cancer chemotherapy and pharmacology

authors： Liu Y,Ren Z,Xu S,Bai H,Ma N,Wang F

更新日期：2015-03-01 00:00:00

abstract：INTRODUCTION:Hormone-refractory disseminated prostate cancer is a major oncological problem. Preclinical studies with temozolomide, an oral alkylating agent, in prostate cancer have shown encouraging results. In phase I studies the safety of temozolomide in non-prostate cancer patients has been demonstrated. Based on t...

journal_title：Cancer chemotherapy and pharmacology

authors： van Brussel JP,Busstra MB,Lang MS,Catsburg T,Schröder FH,Mickisch GH

更新日期：2000-01-01 00:00:00

abstract：:The nephrotoxic interaction between cis-diamminedichloroplatinum (CDDP) and amikacin (AMI) was studied in rats. Following a single dose of CDDP (5 mg/kg i.v.), AMI (60 mg/kg s.c.) was given for 14 days. When given alone CDDP caused a 40% fall in the glomerular filtration rate (GFR), whereas AMI alone had no effect on ...

journal_title：Cancer chemotherapy and pharmacology

authors： Jongejan HT,Provoost AP,Molenaar JC

更新日期：1988-01-01 00:00:00

abstract：PURPOSE:Although chemotherapeutic protocols that include chloroethylnitrosoureas (CENUs), such as 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride (ACNU) and 1, 3-bis(2-chloroethyl)-1-nitrosourea (BCNU), have been a mainstay of treatment for glioblastomas, the clinical outcomes ha...

journal_title：Cancer chemotherapy and pharmacology

authors： Narita Y,Asai A,Kuchino Y,Kirino T

更新日期：2000-01-01 00:00:00

abstract：PURPOSE:To investigate the effect of granulocyte colony-stimulating factor (G-CSF) on the pharmacokinetics and pharmacodynamics of the new morpholino anthracycline drug MX2. METHODS:A total of 25 patients with advanced malignant disease participated in a dose-escalation study in the first cycle of treatment given i.v....

journal_title：Cancer chemotherapy and pharmacology

authors： Morgan DJ,Hill JS,Clarke K,Stylli SS,Park SJ,Cebon J,Basser RL,Kaye AH,Geldard H,Maher DW,Green MD

更新日期：1998-01-01 00:00:00

abstract：PURPOSE:To assess the potential for drug-drug interactions between lenalidomide and substrates and inhibitors of cytochrome P450 (CYP) isozymes. METHODS:In vitro metabolism of lenalidomide by human liver microsomes, recombinant human CYPs and human hepatocytes was evaluated. The inhibitory and inductive effects of len...

journal_title：Cancer chemotherapy and pharmacology

authors： Kumar G,Lau H,Laskin O

更新日期：2009-05-01 00:00:00

abstract：:The effect of acetazolamide (A.A.) on the antineoplastic activity of 1-phthalidyl 5-fluorouracil (PH-FU) against rat and mouse solid tumors was examined. A.A., an inhibitor of liver PH-FU hydrolase, had no antitumor activity but greatly enhanced the activity of PH-FU when coadministered. The potentiation was evaluated...

journal_title：Cancer chemotherapy and pharmacology

authors： Kasai H,Tonda K,Hirata M

更新日期：1986-01-01 00:00:00

abstract：OBJECTIVES:The aim of this phase II study was to evaluate the response rate to gemcitabine combined with cisplatin in patients with locally advanced, metastatic or recurrent biliary tract cancer who had received no prior chemotherapy. METHODS:The treatment consisted of cisplatin 70 mg/m(2) in intravenous infusion foll...

journal_title：Cancer chemotherapy and pharmacology

authors： Lee J,Kim TY,Lee MA,Ahn MJ,Kim HK,Lim HY,Lee NS,Park BJ,Kim JS,Korean Cancer Study Group.

更新日期：2008-01-01 00:00:00

abstract：PURPOSE:To compare the protective effect of dexrazoxane (DRZ) against cardiotoxicity induced by doxorubicin (DXR) and mitoxantrone (MTX). METHODS:Adult male spontaneously hypertensive rats (SHR) were treated with 1 mg/kg DXR (i.v.) or 0.5 mg/kg MTX (i.v.), either alone or 30 min after 25 mg/kg DRZ (i.p.) weekly for up...

journal_title：Cancer chemotherapy and pharmacology

authors： Herman EH,Zhang J,Rifai N,Lipshultz SE,Hasinoff BB,Chadwick DP,Knapton A,Chai J,Ferrans VJ

更新日期：2001-10-01 00:00:00

abstract：BACKGROUND:Expression of the DNA repair protein O (6)-methylguanine-DNA methyltransferase (MGMT) correlates with resistance to irinotecan in colorectal cancer cell lines. This phase I study evaluated the maximum tolerated dose (MTD) of lomeguatrib, an inactivating pseudosubstrate of MGMT, in combination with irinotecan...

journal_title：Cancer chemotherapy and pharmacology

authors： Sabharwal A,Corrie PG,Midgley RS,Palmer C,Brady J,Mortimer P,Watson AJ,Margison GP,Middleton MR

更新日期：2010-10-01 00:00:00

abstract：PURPOSE:This study was performed to determine the maximum tolerated dose (MTD) and toxicity of vinorelbine when used in combination with doxorubicin and methotrexate with leucovorin rescue in women with metastatic breast cancer. METHODS:Enrolled in the study were 23 women with metastatic breast cancer who had not rece...

journal_title：Cancer chemotherapy and pharmacology

authors： Subramanyan S,Abeloff MD,Bond SE,Davidson NE,Fetting JH,Gordon GB,Kennedy MJ

更新日期：1999-01-01 00:00:00

abstract：:Detailed pharmacokinetic analysis and subsequent evaluation of myelotoxicity were performed in 55 patients who had been randomized to 4 different doses of epirubicin (40, 60, 90 or 135 mg/m2 given i.v. every 3 weeks). A significantly positive correlation was demonstrated between the AUC and the myelotoxicity of epirub...

journal_title：Cancer chemotherapy and pharmacology

authors： Jakobsen P,Bastholt L,Dalmark M,Pfeiffer P,Petersen D,Gjedde SB,Sandberg E,Rose C,Nielsen OS,Mouridsen HT

更新日期：1991-01-01 00:00:00

abstract：PURPOSE:The plasma and cerebrospinal fluid (CSF) pharmacokinetics of the camptothecin analogs, 9-aminocamptothecin (9-AC) and irinotecan, were studied in a nonhuman primate model to determine their CSF penetration. METHODS:9-AC, 0.2 mg/kg (4 mg/m2) or 0.5 mg/kg (10 mg/m2), was infused intravenously over 15 min and iri...

journal_title：Cancer chemotherapy and pharmacology

authors： Blaney SM,Takimoto C,Murry DJ,Kuttesch N,McCully C,Cole DE,Godwin K,Balis FM

更新日期：1998-01-01 00:00:00

abstract：PURPOSE:Nasopharyngeal carcinoma (NPC) is one of the most commonly diagnosed cancers worldwide with significantly high prevalence in Southern China. Chemoprevention of cancer with alkylating agent compounds could potentially reverse, suppress, or prevent cancer progression. Cisplatin (CIS) is an antineoplastic or cytot...

journal_title：Cancer chemotherapy and pharmacology

authors： Yin P,Song G,Jiang Z

更新日期：2018-05-01 00:00:00

abstract：PURPOSE:A refined pharmacodynamic model for toxicity is necessary for successful adaptive control of the administration of an anticancer drug to avoid toxicity. We sought to establish a pharmacodynamic model of leukopenia in a 14-day administration of etoposide. METHODS:Pharmacokinetic data of 32 patients treated with...

journal_title：Cancer chemotherapy and pharmacology

authors： Minami H,Ratain MJ,Ando Y,Shimokata K

更新日期：1996-01-01 00:00:00

abstract：PURPOSE:Evodiamine is one of active alkaloids isolated from the traditional Chinese medicine Evodia rutaecarpa Bentham and has various pharmacological properties. In this study, we investigated its effects on the migration, invasion, and associated mechanism in human nasopharyngeal carcinoma (NPC) cells. METHODS:Cell ...

journal_title：Cancer chemotherapy and pharmacology

authors： Peng X,Zhang Q,Zeng Y,Li J,Wang L,Ai P

更新日期：2015-12-01 00:00:00

abstract：PURPOSE:SU5416 is a novel small organic molecule that non-competitively inhibits the phosphorylation of the VEGF tyrosine kinase receptor, Flk-1. This phase IB study was performed to determine the safety, pharmacokinetics, and preliminary efficacy of the combination of SU5416 and paclitaxel in recurrent or metastatic c...

journal_title：Cancer chemotherapy and pharmacology

authors： Cooney MM,Tserng KY,Makar V,McPeak RJ,Ingalls ST,Dowlati A,Overmoyer B,McCrae K,Ksenich P,Lavertu P,Ivy P,Hoppel CL,Remick S

更新日期：2005-03-01 00:00:00